NAFLD Biomarker

Explore the latest advances in biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Stay informed about these key tools for diagnosis and management.

PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Authors: Staels B, Butruille L, Francque S
Published in Journal of Hepatology (July 2023)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways. Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data

Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

Authors: Li YY, Zheng TL, Xiao SY et al.
Published in Liver International (June 2023)
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
Read MoreBallooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Authors: Vonderlin J, Chavakis T, Sieweke M et al.
Published in Cellular and Molecular Gastroenterology and Hepatology (March 2023)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?

MASLD: A New Fatty Liver Disease Nomenclature?

Authors: Rinella ME, Lazarus JV, Ratziu V et al.
Published in Journal of Hepatology (June 2023)
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Read MoreMASLD: A New Fatty Liver Disease Nomenclature?

Measuring NAFLD Models of Care: A New Strategic Framework?

Authors: Allen AM, Younossi ZM, Tsochatzis EA et al.
Published in Nature Reviews: Gastroenterology and Hepatology (June 2023)
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Read MoreMeasuring NAFLD Models of Care: A New Strategic Framework?

Biomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

Authors: Rasmussen DGK, Anstee QM, Torstenson R et al.
Published in Journal of Hepatology (April 2023)
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.
Read MoreBiomarker Qualification for NAFLD and NASH: Insights from the LITMUS Consortium

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES